CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...
HKG: 2616
CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC
China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...
CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma
China-based CStone Pharmaceuticals (HKG: 2616) has announced a Phase Ib clinical filing in Australia for...
CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America
China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered...
CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...
CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009
China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4...
CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa
China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...
CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting
China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...
CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...
CStone Pharmaceuticals’ Partner HengRui Medicine Launches Phase III Trial for CTLA-4 Antibody in HCC
CStone Pharmaceuticals (HKG: 2616), an innovation-driven biopharmaceutical company focused on the development of oncology drugs,...
CStone Pharmaceuticals’ Sugemalimab Shows Promising Long-Term Survival Data at ESMO 202
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has presented long-term treatment and...
CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones
CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...
CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...
CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...
CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...
CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
CStone Pharmaceuticals Expands European Reach with Ewopharma Partnership for Sugemalimab
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a strategic partnership...
CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...